Mallinckrodt plc Reports Fiscal 2014 Third Quarter Financial Results; Updates Full-Year 2014 Guidance, Increasing Net Sales And Adjusted Diluted Earnings Per Share

Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today reported results for the third quarter of fiscal 2014, which ended June 27, 2014. The company also announced that it updated guidance for fiscal 2014 reflecting the strong performance of the company’s base business, and recently acquired OFIRMEV (acetaminophen) injection.

Help employers find you! Check out all the jobs and post your resume.